ProShare Advisors LLC Cuts Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS)

ProShare Advisors LLC decreased its holdings in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) by 34.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 46,553 shares of the company’s stock after selling 24,051 shares during the period. ProShare Advisors LLC’s holdings in Xeris Biopharma were worth $158,000 at the end of the most recent reporting period.

Other institutional investors have also added to or reduced their stakes in the company. Legato Capital Management LLC purchased a new position in Xeris Biopharma during the 4th quarter valued at about $482,000. Connor Clark & Lunn Investment Management Ltd. grew its position in shares of Xeris Biopharma by 106.2% in the 4th quarter. Connor Clark & Lunn Investment Management Ltd. now owns 171,332 shares of the company’s stock worth $581,000 after buying an additional 88,224 shares during the last quarter. Vanguard Group Inc. grew its position in shares of Xeris Biopharma by 1.7% in the 4th quarter. Vanguard Group Inc. now owns 7,899,063 shares of the company’s stock worth $26,778,000 after buying an additional 133,738 shares during the last quarter. Principal Financial Group Inc. grew its position in shares of Xeris Biopharma by 10.5% in the 4th quarter. Principal Financial Group Inc. now owns 113,217 shares of the company’s stock worth $384,000 after buying an additional 10,748 shares during the last quarter. Finally, Raymond James Financial Inc. purchased a new position in shares of Xeris Biopharma in the 4th quarter worth approximately $45,000. Hedge funds and other institutional investors own 42.75% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on XERS. Leerink Partners lifted their price objective on shares of Xeris Biopharma from $5.00 to $6.00 and gave the stock an “outperform” rating in a research report on Friday, March 7th. HC Wainwright reiterated a “buy” rating and issued a $8.00 target price (up from $6.60) on shares of Xeris Biopharma in a research note on Friday, March 7th. Oppenheimer lifted their target price on shares of Xeris Biopharma from $6.00 to $7.00 and gave the stock an “outperform” rating in a research note on Friday, May 9th. Piper Sandler reiterated a “neutral” rating and issued a $4.00 target price (up from $3.00) on shares of Xeris Biopharma in a research note on Friday, March 7th. Finally, Wall Street Zen cut shares of Xeris Biopharma from a “buy” rating to a “hold” rating in a research note on Thursday, May 22nd. Two analysts have rated the stock with a hold rating and five have issued a buy rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $6.25.

Xeris Biopharma Trading Down 2.2%

Shares of NASDAQ XERS opened at $4.93 on Monday. Xeris Biopharma Holdings, Inc. has a 12 month low of $2.03 and a 12 month high of $6.07. The company has a 50 day simple moving average of $4.65 and a two-hundred day simple moving average of $4.03. The stock has a market cap of $770.98 million, a price-to-earnings ratio of -10.96 and a beta of 1.10.

Xeris Biopharma (NASDAQ:XERS) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.07) by $0.01. The business had revenue of $57.80 million for the quarter, compared to analyst estimates of $57.61 million. Analysts forecast that Xeris Biopharma Holdings, Inc. will post -0.41 EPS for the current year.

Insider Buying and Selling at Xeris Biopharma

In other news, insider Beth Hecht sold 40,000 shares of Xeris Biopharma stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $5.43, for a total transaction of $217,200.00. Following the completion of the transaction, the insider now directly owns 1,353,510 shares of the company’s stock, valued at $7,349,559.30. The trade was a 2.87% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 6.47% of the company’s stock.

Xeris Biopharma Company Profile

Xeris Biopharma Holdings, Inc, a biopharmaceutical company, engages in developing and commercializing therapies in Illinois. The company offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor proved for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.